What documentation is commonly needed for GLP-1 prior authorization under commercial insurance?

Insurers typically require medical records proving a qualifying diagnosis, like type 2 diabetes or a specific BMI, and documentation of failed alternative therapies.

Core Documentation for GLP-1 Prior Authorization

Prior authorization (PA) is a process used by insurance companies to verify that a prescribed medication is medically necessary. For GLP-1 receptor agonists, this means your physician must submit clinical documentation proving you meet the insurer's specific criteria for coverage.

The core of any PA submission is your medical record. This includes detailed chart notes from office visits, relevant lab results (such as HbA1c or lipid panels), and the specific diagnosis codes (ICD-10) that justify the prescription.

Your physician's office will typically complete a specific PA form provided by the insurer or a pharmacy benefit manager (PBM). This form organizes your diagnostic information, treatment history, and the physician's clinical rationale for prescribing the GLP-1 medication.

A complete submission tells a clear story to the insurance reviewer, demonstrating why the requested medication is the appropriate next step in your physician-supervised treatment plan. Missing information is a common reason for initial denial.

Proving Medical Necessity for Weight Management

For GLP-1s approved for chronic weight management, like Wegovy (semaglutide) and Zepbound (tirzepatide), documentation must support a diagnosis of obesity or overweight with complications. Insurers adhere closely to FDA-approved indications.

Typically, you must have a documented body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbid condition. These conditions include hypertension, type 2 diabetes, or dyslipidemia (high cholesterol).

Your medical records must contain evidence of these comorbidities. For example, a diagnosis of hypertension should be supported by multiple blood pressure readings, and dyslipidemia should be supported by a recent lipid panel.

Many insurance plans also require proof of participation in a comprehensive [weight-loss](/weight-loss) program for a period of 3 to 6 months prior to the PA request. This involves documenting efforts with diet, exercise, and sometimes behavioral counseling.

Criteria for Type 2 Diabetes Management

When seeking coverage for GLP-1s indicated for type 2 diabetes (T2D), such as Ozempic, Mounjaro, or Rybelsus, the primary requirement is a documented diagnosis of T2D. This is typically coded as ICD-10 code E11.

Insurers will require recent laboratory results to confirm the diagnosis and establish a baseline for treatment. The most important lab value is the Hemoglobin A1c (HbA1c), which reflects your average blood sugar over the past three months.

While a T2D diagnosis is essential, it is often not sufficient on its own. Most plans impose additional requirements, most commonly 'step therapy,' before they will approve a brand-name GLP-1 medication.

Navigating Step Therapy and Formulary Rules

Step therapy is a common requirement where a patient must first try and 'fail' one or more lower-cost, preferred medications before the insurer will cover a more expensive drug. For T2D, this almost always means a trial of metformin.

Documentation must clearly show that you have used the preferred alternative(s) for a sufficient period (e.g., 90 days) and that the treatment was either not effective enough (e.g., HbA1c did not improve) or caused intolerable side effects.

Every insurance plan has a formulary, which is its list of covered drugs. One GLP-1 may be 'preferred' over another. If your physician prescribes a non-preferred GLP-1, the PA must include a clinical justification for why the formulary's preferred option is not appropriate for you.

Simply wanting a specific brand is not a valid reason for approval. The justification must be clinical, such as a history of a specific side effect with a similar preferred medication or a unique comorbidity that favors the non-preferred drug.

Your Physician's Role in the Process

Your healthcare provider and their staff are responsible for gathering the necessary documents and submitting the prior authorization request. They act as your advocate in communicating your medical need to the insurance company.

A key part of the submission is often a 'Letter of Medical Necessity.' In this letter, your physician summarizes your diagnosis, treatment history, the failure of other therapies, and the clinical evidence supporting the use of the requested GLP-1.

Strong, consistent documentation over time is the most critical element for a successful PA. A long-standing record of managing your condition provides more compelling evidence than a single recent visit.

The PA process can sometimes require multiple submissions or appeals. Maintaining open communication with your physician's office can help you stay informed on the status and any additional information that may be needed.

Bottom Line

Securing prior authorization for a GLP-1 medication typically requires your physician to submit detailed medical records that prove a qualifying diagnosis (type 2 diabetes or specific BMI criteria), document the failure of preferred alternative medications (step therapy), and justify the medical necessity of the prescription.

Requirements vary significantly between commercial insurance plans. Before starting the process, it is wise to check your plan's specific drug formulary and published clinical policies for GLP-1 agonists.

This article is for educational purposes only and is not a substitute for professional medical advice. Consult with a healthcare provider to determine the best treatment plan for you.

Generated from GOAL.MD's physician-reviewed source library. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.